MitoTam (bromide, hydrobromide)

• UNSPSC Description:

  MitoTam bromide, hydrobromide, a Tamoxifen derivative[1], is an electron transport chain (ETC) inhibitor. MitoTam bromide, hydrobromide reduces mitochondrial membrane potential in senescent cells and affects mitochondrial morphology[2]. MitoTam bromide, hydrobromide is an effective anticancer agent, suppresses respiratory complexes (CI-respiration) and disrupts respiratory supercomplexes (SCs) formation in breast cancer cells[1][2].

• Target Antigen:

  Apoptosis; Mitochondrial Metabolism

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mitotam-bromide-hydrobromide.html

• Purity:

  98.24

• Solubility:

  DMSO : 240 mg/mL (ultrasonic)

• Smiles:

  CN(CCOC1=CC=C(/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/CCCCCCCCCC[P+](C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)C=C1)C.Br[H].[Br-]

• Molecular Weight:

  905.82

• References & Citations:

  [1]Rohlenova K, et al. Selective Disruption of Respiratory Supercomplexes as a New Strategy to Suppress Her2highBreast Cancer. Antioxid Redox Signal. 2017 Jan 10;26(2):84-103.|[2]Hubackova S, et al. Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2. Cell Death Differ. 2019 Jan;26(2):276-290.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  1634624-73-9